- Home
- RVTY vs KRYS Comparison
RVTY vs KRYS Comparison
Compare RVTY & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RVTY | KRYS |
|---|---|---|
| Founded | 1937 | 2015 |
| Country | United States | United States |
| Employees | N/A | 295 |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 9.6B |
| IPO Year | 1994 | 2017 |
Fundamental Metrics
Financial Performance| Metric | RVTY | KRYS |
|---|---|---|
| Price | $114.83 | $326.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 11 |
| Target Price | $109.67 | ★ $297.60 |
| AVG Volume (30 Days) | ★ 1.5M | 610.8K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.34% | N/A |
| EPS Growth | N/A | ★ 128.00 |
| EPS | 0.36 | ★ 3.62 |
| Revenue | ★ $3,311,822,000.00 | $389,130,000.00 |
| Revenue This Year | $6.37 | $38.74 |
| Revenue Next Year | $5.10 | $32.53 |
| P/E Ratio | $317.33 | ★ $89.14 |
| Revenue Growth | N/A | ★ 33.94 |
| 52 Week Low | $81.22 | $137.38 |
| 52 Week High | $118.30 | $382.54 |
Technical Indicators
Market Signals| Indicator | RVTY | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 56.46 | 42.36 |
| Support Level | $92.05 | $318.87 |
| Resistance Level | $116.82 | $377.89 |
| Average True Range (ATR) | 4.58 | 17.00 |
| MACD | -0.01 | -4.08 |
| Stochastic Oscillator | 79.14 | 35.66 |
Price Performance
Historical ComparisonAbout RVTY Revvity Inc.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.